Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
Juri KiyokawaYoichiro KawamuraShanawaz M GhouseSimge AcarErinç BarçınJordi Martínez-QuintanillaRobert L MartuzaRamon AlemanySamuel D RabkinKhalid ShahHiroaki WakimotoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Our studies are the first to show that immune modulatory ICOVIR17 has a dual role of mediating degradation of HA within GBM ECM and subsequently modifying the immune landscape of the TME, and offers a mechanistic combination immunotherapy with PD-L1/PD-1 blockade that remodels innate and adaptive immune cells.